SAGE - Sage Therapeutics Inc Stock Price, Fair Value and News

12.37USD-0.61 (-4.70%)Market Closed

Market Summary

USD12.37-0.61

Market Closed

-4.70%

SAGE Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

SAGE Stock Price

View Fullscreen

SAGE RSI Chart

SAGE Valuation

Market Cap

781.2M

Price/Earnings (Trailing)

-1.55

Price/Sales (Trailing)

8.58

Price/Free Cashflow

-1.84

SAGE Price/Sales (Trailing)

SAGE Profitability

Operating Margin

98.37%

Return on Equity

-71.29%

Return on Assets

-65.55%

Free Cashflow Yield

-54.41%

SAGE Fundamentals

SAGE Revenue

Revenue (TTM)

91.1M

Rev. Growth (Yr)

139.89%

Rev. Growth (Qtr)

-89.87%

SAGE Earnings

Earnings (TTM)

-503.1M

Earnings Growth (Yr)

26.12%

Earnings Growth (Qtr)

-231.69%

Breaking Down SAGE Revenue

52 Week Range

12.2859.99

(Low)(High)

Last 7 days

-6.9%

Last 30 days

-20.9%

Last 90 days

-45.7%

Trailing 12 Months

-74.8%

How does SAGE drawdown profile look like?

SAGE Financial Health

Current Ratio

12.22

SAGE Investor Care

Shares Dilution (1Y)

0.70%

Diluted EPS (TTM)

-8.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	91.1M	0	0	0
2023	9.4M	10.4M	11.3M	86.5M
2022	6.3M	6.2M	6.5M	7.7M
2021	837.2M	560.3M	283.3M	6.3M
2020	7.9M	8.9M	561.6M	1.1B
2019	0	62.5M	34.7M	6.9M
2018	0	0	0	90.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Sage Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 13, 2024	iguchi kimi	acquired	-	-	11,250	cfo & treasurer
Feb 13, 2024	cook anne marie	acquired	-	-	11,250	svp, gc & secretary
Feb 13, 2024	gault laura	acquired	-	-	11,250	chief medical officer
Feb 13, 2024	benecchi christopher	acquired	-	-	13,500	chief business officer
Jan 02, 2024	iguchi kimi	acquired	2,233	1.36	1,642	cfo & treasurer
Nov 28, 2023	iguchi kimi	sold (taxes)	-18,171	19.27	-943	cfo & treasurer
Nov 28, 2023	jonas jeffrey m	sold (taxes)	-75,827	19.27	-3,935	-
Nov 28, 2023	iguchi kimi	acquired	-	-	3,500	cfo & treasurer
Nov 28, 2023	cook anne marie	sold (taxes)	-22,623	19.27	-1,174	svp, gc & secretary
Nov 28, 2023	cook anne marie	acquired	-	-	4,000	svp, gc & secretary

Which funds bought or sold SAGE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	DiNuzzo Private Wealth, Inc.	unchanged	-	-15.00	94.00	-%
May 06, 2024	NEW YORK LIFE INVESTMENT MANAGEMENT LLC	new	-	358,890	358,890	-%
May 06, 2024	Candriam S.C.A.	reduced	-2.2	-759,033	4,160,280	0.03%
May 06, 2024	ORG Partners LLC	sold off	-100	-108	-	-%
May 06, 2024	Parallel Advisors, LLC	unchanged	-	-2,895	18,515	-%
May 06, 2024	SouthState Corp	unchanged	-	-26.00	169	-%
May 06, 2024	Jefferies Financial Group Inc.	added	436	2,297,180	2,791,100	0.02%
May 06, 2024	TEACHER RETIREMENT SYSTEM OF TEXAS	reduced	-3.54	-45,000	225,000	-%
May 03, 2024	SIGNATUREFD, LLC	reduced	-35.63	-5,150	6,465	-%
May 03, 2024	EASTERLY INVESTMENT PARTNERS LLC	reduced	-10.63	-603,733	2,053,940	0.16%

Are Funds Buying or Selling SAGE?

Are funds buying SAGE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SAGE

No. of Funds

Unveiling Sage Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	rtw investments, lp	8.7%	5,197,019	SC 13G
Feb 13, 2024	bb biotech ag	5.8%	3,505,000	SC 13G/A
Feb 13, 2024	vanguard group inc	8.86%	5,319,360	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	10.10%	6,061,996	SC 13G/A
Jan 26, 2024	blackrock inc.	7.8%	4,663,900	SC 13G/A
Jan 24, 2024	state street corp	6.53%	3,918,222	SC 13G
Jul 10, 2023	wellington management group llp	10.65%	6,363,630	SC 13G/A
Feb 17, 2023	bb biotech ag	5.2%	3,100,278	SC 13G
Feb 14, 2023	bb biotech ag	5.0%	2,950,278	SC 13G/A

Recent SEC filings of Sage Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	10-Q	Quarterly Report
Apr 25, 2024	8-K	Current Report
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 19, 2024	8-K	Current Report
Apr 17, 2024	8-K	Current Report
Mar 27, 2024	SC TO-I/A	SC TO-I/A
Mar 26, 2024	8-K	Current Report
Feb 21, 2024	SC TO-I/A	SC TO-I/A

Peers (Alternatives to Sage Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Sage Therapeutics Inc News

Latest updates

Sage Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	-89.9%	7,902,000	77,971,500	2,716,000	2,474,000	3,294,000	2,864,500	1,739,000	1,501,000	1,582,000	1,642,000	1,440,000	1,643,000	1,504,500	1,366,000	1,227,500	1,089,000	2,286,000	1,960,000	3,570,000	25,177,500	46,785,000
Cost Of Revenue	-	-	-	905,000	205,000	230,000	143,000	184,000	200,000	286,000	87,000	131,000	148,000	187,000	136,000	149,000	110,000	170,000	-	137,000	44,000	-
Operating Expenses	4.6%	125,577,000	120,045,000	214,565,000	172,931,000	158,764,000	156,767,000	143,219,000	129,908,000	124,781,000	127,129,000	132,334,000	109,664,000	98,090,000	135,211,000	108,797,000	140,056,000	133,910,000	176,598,000	190,747,000	177,330,000	164,500,000
S&GA Expenses	-4.6%	52,574,000	55,109,000	78,142,000	75,565,000	65,708,000	67,329,000	61,482,000	52,411,000	46,477,000	51,599,000	48,706,000	43,346,000	39,847,000	53,498,500	35,099,000	38,224,000	70,130,000	85,129,000	88,502,000	88,227,000	75,695,000
R&D Expenses	11.5%	71,734,000	64,329,500	101,919,000	97,161,000	92,826,000	89,295,000	81,553,000	77,297,000	78,018,000	75,443,000	83,497,000	66,170,000	58,056,000	81,706,000	74,078,000	73,320,000	63,610,000	91,250,000	102,108,000	89,059,000	88,805,000
EBITDA Margin	-	-	-	-	-	-	-	-	-74.06	-73.13	-71.93	-	-	0.54	0.54	-1.21	-76.26	-26.97	-16.38	-6.44	-5.02	-
EBT Margin	-	-	-	-	-	-	-	-	-74.27	-73.42	-72.59	-	-	0.54	0.54	-1.21	-76.39	-27.02	-16.41	-6.46	-5.04	-
Net Income	-231.7%	-108,483,000	-32,706,000	-201,630,000	-160,325,000	-146,828,000	-147,146,000	-137,323,000	-126,260,000	-122,055,000	-124,712,000	-130,171,000	-107,245,000	-95,764,000	974,895,000	-105,735,000	-136,347,000	-126,740,000	-168,653,000	-179,958,000	-168,221,000	-158,388,000
Net Income Margin	11.8%	-5.53	-6.26	-57.80	-57.04	-59.32	-69.31	-78.95	-81.62	-76.77	-72.59	2.27	1.19	-	-	-	-	-	-	-	-	-
Free Cashflow	68.3%	-37,832,000	-119,407,000	-136,194,000	-131,630,000	-153,907,000	-127,214,000	-119,229,000	-106,561,000	-107,969,000	-97,501,000	-68,826,000	-102,769,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-13.0%	768	882	950	1,082	1,221	1,356	1,486	1,601	1,706	1,825	1,927	2,015	2,081	2,159	739	827	945	1,084	1,204	1,316	1,423
Current Assets	-13.1%	755	869	933	1,064	1,203	1,337	1,465	1,579	1,682	1,801	1,902	1,989	2,052	2,122	699	785	898	1,035	1,153	1,264	1,372
Cash Equivalents	143.2%	173	71.00	149	121	207	163	200	207	179	294	422	514	899	1,661	184	258	199	127	259	166	342
Net PPE	-17.5%	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	7.00	7.00	8.00	9.00	9.00	9.00	8.00	7.00
Liabilities	-25.3%	62.00	83.00	133	98.00	88.00	104	106	97.00	87.00	96.00	92.00	86.00	77.00	87.00	81.00	87.00	96.00	139	123	113	103
Current Liabilities	-25.3%	62.00	83.00	133	97.00	85.00	99.00	100	89.00	78.00	85.00	79.00	72.00	62.00	67.00	60.00	64.00	70.00	112	91.00	79.00	68.00
Shareholder's Equity	-11.7%	706	800	817	984	1,133	1,253	1,380	1,504	1,619	1,729	1,836	1,930	2,003	2,072	658	740	849	945	1,081	1,203	1,320
Retained Earnings	-4.2%	-2,678	-2,569	-2,536	-2,335	-2,175	-2,028	-1,881	-1,743	-1,617	-1,495	-1,370	-1,240	-1,100	-1,037	-2,012	-1,900	-1,770	-1,643	-1,474	-1,300	-1,126
Additional Paid-In Capital	0.4%	3,385	3,370	3,358	3,326	3,314	3,291	3,276	3,262	3,248	3,227	3,207	3,171	3,137	3,110	2,669	2,645	2,621	2,587	2,555	2,497	2,447
Shares Outstanding	0.2%	60.00	60.00	60.00	60.00	60.00	60.00	59.00	59.00	59.00	59.00	59.00	58.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,471	-	-	-	1,686	-	-	-	2,934	-	-	-	2,121	-	-	-	9,274	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	68.3%	-37,832	-119,519	-135,866	-131,518	-153,682	-126,932	-118,865	-106,439	-107,800	-97,501	-68,826	-102,769	-109,086	1,010,971	-91,016	-118,984	-136,691	-116,726	-128,702	-133,344	-149,934
Share Based Compensation	5.8%	13,698	12,945	28,691	11,693	20,038	15,244	13,169	14,636	18,553	20,648	34,342	27,663	21,976	20,744	20,108	24,032	31,110	30,679	43,669	34,767	44,116
Cashflow From Investing	231.5%	139,436	42,061	160,392	45,593	194,867	89,777	110,952	134,262	-9,558	-30,261	-24,983	-288,388	-658,816	45,519	13,513	177,382	206,270	-17,916	207,779	-58,109	-274,910
Cashflow From Financing	694.3%	1,557	-262	2,770	847	2,672	29.00	1,229	13.00	1,799	-170	1,816	6,065	5,623	419,671	3,545	386	3,160	2,166	13,919	15,343	576,196

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SAGE Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 7,902	$ 3,294
Operating costs and expenses:
Cost of revenues	1,269	230
Research and development	71,734	92,826
Selling, general and administrative	52,574	65,708
Total operating costs and expenses	125,577	158,764
Loss from operations	(117,675)	(155,470)
Interest income, net	9,204	8,830
Other expense, net	(12)	(188)
Net loss	$ (108,483)	$ (146,828)
Net loss per share - basic	$ (1.8)	$ (2.46)
Net loss per share - diluted	$ (1.8)	$ (2.46)
Weighted average number of common shares outstanding— basic	60,136,198	59,674,127
Weighted average number of common shares outstanding— diluted	60,136,198	59,674,127
Comprehensive loss:
Net loss	$ (108,483)	$ (146,828)
Other comprehensive items:
Unrealized gain on marketable securities	27	5,118
Total comprehensive loss	(108,456)	(141,710)
Product Revenue [Member]
Total revenue	1,690	$ 3,294
Collaboration Revenue - Related Party [Member]
Total revenue	$ 6,212

SAGE Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 172,653	$ 70,992
Marketable securities	544,360	682,192
Prepaid expenses and other current assets	26,588	31,825
Collaboration receivable - related party	10,509	83,009
Restricted cash	$ 1,332	$ 1,332
Accounts Receivable, after Allowance for Credit Loss, Current, Related Party, Type [Extensible Enumeration]	Related Party [Member]	Related Party [Member]
Total current assets	$ 755,442	$ 869,350
Property and equipment, net	1,585	1,921
Restricted cash	1,500	0
Right-of-use operating asset	2,857	4,458
Other long-term assets	6,216	6,548
Total assets	767,600	882,277
Current liabilities:
Accounts payable	6,479	10,318
Accrued expenses	52,014	67,264
Operating lease liability, current portion	3,306	5,165
Total current liabilities	61,799	82,747
Total liabilities	61,799	82,747
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value per share; 120,000,000 shares authorized at March 31, 2014 and December 31, 2023; 60,185,064 and 60,046,676 shares issued at March 31, 2024 and December 31, 2023; 60,182,031 and 60,043,643 shares outstanding at March 31,2024 and December 31, 2023	6	6
Treasury stock, at cost, 3,033 shares at March 31, 2024 and December 31, 2023	(400)	(400)
Additional paid-in capital	3,385,124	3,370,397
Accumulated deficit	(2,678,142)	(2,569,659)
Accumulated other comprehensive loss	(787)	(814)
Total stockholders’ equity	705,801	799,530
Total liabilities and stockholders’ equity	$ 767,600	$ 882,277

About Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Barry E. Greene
WEBSITE	sagerx.com
INDUSTRY	Biotechnology
EMPLOYEES	689

Sage Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Sage Therapeutics Inc? What does SAGE stand for in stocks?

SAGE is the stock ticker symbol of Sage Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sage Therapeutics Inc (SAGE)?

As of Tue May 07 2024, market cap of Sage Therapeutics Inc is 781.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SAGE stock?

You can check SAGE's fair value in chart for subscribers.

What is the fair value of SAGE stock?

You can check SAGE's fair value in chart for subscribers. The fair value of Sage Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sage Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SAGE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sage Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SAGE is over valued or under valued. Whether Sage Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sage Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SAGE.

What is Sage Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, SAGE's PE ratio (Price to Earnings) is -1.55 and Price to Sales (PS) ratio is 8.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SAGE PE ratio will change depending on the future growth rate expectations of investors.